Navigation Links
AutoGenomics Receives FDA Clearance for its INFINITI(TM) Warfarin Assay

CARLSBAD, Calif., Jan. 24 /PRNewswire/ -- AutoGenomics, a leader in developing automated molecular testing solutions announced today that it has obtained clearance from the Food and Drug Administration (FDA) for its INFINITI 2C9-VKORC1 Multiplex Assay for Warfarin. The company has already received FDA clearance for its INFINITI Analyzer and FII/FV assays in 2007.

"We are excited to receive FDA clearance for our warfarin test," said Fareed Kureshy, President and CEO of AutoGenomics. "The FDA recently re- labeled warfarin stating that genetic testing may help optimize the use of the drug and lower the risk of bleeding complications. Several of our customers are awaiting such clearance to implement testing in their practice. We continue to expand our product portfolio with additional warfarin assays and are committed to be the lead player in this testing arena."

About AutoGenomics

AutoGenomics Inc., a privately held company based in Carlsbad, CA, has developed the first automated, microarray based multiplexing diagnostic platforms that can be used to assess disease signatures with novel genomic and proteomic markers in the area of genetic disorders, infectious disease, cancer and pharmacogenetics. With the discovery of genes and their link to various disease states the platform has the versatility to revolutionize the way patients are diagnosed, monitored and managed leading to the era of personalized medicine.

SOURCE AutoGenomics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Siemens Receives FDA 510(K) Clearance for Next Generation Radiation Therapy Solution
2. ImmunoVaccine Technologies Receives $3 Million From ACOA
3. Nerites Receives NIH Grant to Study Novel Treatment for Preventing Dangerous Bacterial Infections on Urinary Stents and Catheters
4. Welchol(TM) (colesevelam HCl) Receives FDA Approval to Reduce Blood Glucose in Adults with Type 2 Diabetes
6. Novadaqs SPY System receives clearance for use in organ transplant surgery
7. BeneChills RhinoChill System Receives CE Marking for European Commercial Sale
8. e-Health Card Terminal From SCM Microsystems Receives GEMATIK Certification
9. Breckenridge Pharmaceutical Settles Paragraph IV Litigation and Receives FDA Approval for its Oxcarbazepine ANDA
10. LifeMasters Receives Full URAC Disease Management Accreditation
11. Federal Government Receives Failing Grades on Tobacco Control in Annual American Lung Association Report
Post Your Comments:
(Date:11/24/2015)... ... 24, 2015 , ... Preparing for the LDT Regulation:, CLIA Won’t Satisfy the ... , FDA has long asserted that design and manufacture of Laboratory Developed Tests ... do not meet the device regulations. , Come up short in an inspection and ...
(Date:11/24/2015)... ... November 24, 2015 , ... Brillouin Energy Corp. Congress and ... developer of renewable energy technologies capable of producing commercially useful amounts of thermal ... its WET™ and HHT™ Boiler System reactor core modules were presented to Congress ...
(Date:11/24/2015)... , ... November 24, 2015 , ... ... to share their knowledge and experiences at a live taping of the next ... Center for the Cure of Gastrointestinal Cancers 2015 Symposium at Georgetown University Hotel ...
(Date:11/24/2015)... ... 2015 , ... Serenity Point Rehabilitation, a holistic treatment center for substance abuse ... of the staff members at their recovery center. The videos highlight some of the ... of the things that make their recovery program so unique. , “Making the decision ...
(Date:11/24/2015)... ... ... Shoulder , LLC launched their Pro Vest, the latest version of their widely popular weight ... under 10 hours. , The campaign, which will continue to run through ... market. , The PRO Vest provides consumers with a less expensive, one-size fits all comfort ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... , Nov. 24, 2015  Thanks to a donor ... St. Mary,s Medical Center,s Sister Diane Grassilli Center for ... capabilities in San Francisco . ... friend, stepped forward with a gift of $617,320 that ... Digital Mammography with Tomosynthesis and Whole Breast Ultrasound. Tomosynthesis, ...
(Date:11/24/2015)... 2015 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the ... that the first patient has been enrolled in ESSA,s ... for metastatic castration-resistant prostate cancer ("mCRPC"). ... --> the United States and ... clinical trial, ESSA intends to demonstrate the safety, tolerability, ...
(Date:11/24/2015)... --> --> ... by Product Type (Bone Graft, Bine Graft Substitute, Platelet Rich ... Lumbar Interbody Fusion), End User, and Geography - Global Forecast ... at $1.90 Billion in 2014 and is expected to reach ... the forecast period of 2015 to 2020. Browse ...
Breaking Medicine Technology: